Cone beam computed tomography: An accurate imaging technique in comparison with orthogonal portal imaging in intensity-modulated radiotherapy for prostate cancer
Purpose: Various factors cause geometric uncertainties during prostate radiotherapy, including interfractional and intrafractional patient motions, organ motion, and daily setup errors. This may lead to increased normal tissue complications when a high dose to the prostate is administered. More-accurate treatment delivery is possible with daily imaging and localization of the prostate. This study aims to measure the shift of the prostate by using kilovoltage (kV) cone beam computed tomography (CBCT) after position verification by kV orthogonal portal imaging (OPI).
Methods: Position verification in 10 patients with prostate cancer was performed by using OPI followed by CBCT before treatment delivery in 25 sessions per patient. In each session, OPI was performed by using an on-board imaging (OBI) system and pelvic bone-to-pelvic bone matching was performed. After applying the noted shift by using OPI, CBCT was performed by using the OBI system and prostate-to-prostate matching was performed. The isocenter shifts along all three translational directions in both techniques were combined into a three-dimensional (3-D) iso-displacement vector (IDV).
Results: The mean (SD) IDV (in centimeters) calculated during the 250 imaging sessions was 0.931 (0.598, median 0.825) for OPI and 0.515 (336, median 0.43) for CBCT, p-value was less than 0.0001 which shows extremely statistical significant difference.
Conclusion: Even after bone-to-bone matching by using OPI, a significant shift in prostate was observed on CBCT. This study concludes that imaging with CBCT provides a more accurate prostate localization than the OPI technique. Hence, CBCT should be chosen as the preferred imaging technique.
World Cancer Report 2014. World Health Organization: Geneva; 2014.
Isa M, Rehman J, Afzal M, Chow JC. Dosimetric dependence on the collimator angle in prostate volumetric modulated arc therapy. Int J Cancer Ther Oncol. 2014;2:020419.
Rana S, Larson G, Vargas C, et al. Intensity modulated proton therapy versus uniform scanning proton therapy: Treatment planning study of the prostate cancer in patients with a unilateral metallic hip prosthesis. Jour Proton Ther. 2015;1:113.
Sawant S, Shegokar R. Cancer research and therapy: Where are we today? Int J Cancer Ther Oncol. 2014; 2:02048.
Wong JR, Gao Z, Uematsu M, et al. Interfractional prostate shifts: review of 1870 computed tomography (CT) scans obtained during image-guided radiotherapy using CT-on-rails for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:1396-401.
Hunt MA, Schultheiss TE, Desobry GE, et al. An evaluation of setup uncertainties for patients treated to pelvic sites. Int J Radiat Oncol Biol Phys. 1995;32:227-33.
Bentel GC, Marks LB, Sherouse GW, et al. The effectiveness of immobilization during prostate irradiation. Int J Radiat Oncol Biol Phys. 1995;31:143-8.
Russo GA, Qureshi MM, Truong MT, et al. Daily orthogonal kilovoltage imaging using a gantry-mounted on-board imaging system results in a reduction in radiation therapy delivery errors. Int J Radiat Oncol Biol Phys. 2012;84:596-601.
Gurjar OP, Mishra SP, Bhandari V, et al. A study on the necessity of kV-CBCT imaging compared to kV-Orthogonal portal imaging based on setup errors: Considering other socioeconomical factors. J Can Res Ther. 2014;10:583-6.
Ullman KL, Ning H, Susil RC, et al. Intra-and inter-radiation therapist reproducibility of daily isocenter verification using prostate fiducial markers. Radiat Oncol. 2006;1:2.
Sveistrup J, af Rosenschöld PM, Deasy JO, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014;9:44.
ICRU Report 83. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). International Commission on Radiation Units and Measurements, Bethesda; 2010.
Mechalakos JG, Hunt MA, Lee NY, et al. Using an onboard kilovoltage imager to measure setup deviation in intensity-modulated radiation therapy for head-and-neck patients. J Appl Clin Med Phys. 2007;8:2439.
Zelefsky MJ, Crean D, Mageras GS, et al. Quantification and Predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol. 1999; 50:225-34.
Barney BM, Lee RJ, Handrahan D, et al. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT). Int J Radiat Oncol Biol Phys. 2011;80:301-5.
Aubry JF, Beaulieu L, Girouard LM, et al. Measurements of intrafraction motion and interfraction and intrafraction rotation of prostate by three-dimensional analysis of daily portal imaging with radiopaque markers. Int J Radiat Oncol Biol Phys. 2004;60:30-9.
Walter C, Boda-Heggemann J, Wertz H, et al. Phantom and in-vivo measurements of dose exposure by image-guided radiotherapy (IGRT): MV portal images vs. kV portal images vs. cone-beam CT. Radiother Oncol. 2007; 85:418-23.
Adamczyk M, Piotrowski T, Adamiak E. Evaluation of combining bony anatomy and soft tissue position correction strategies for IMRT prostate cancer patients. Rep Pract Oncol Radiother. 2012;17:104-9.
Schild SE, Casale HE, Bellefontaine LP. Movements of the prostate due torectal and bladder distension: implications for radiotherapy. Med Dosim. 1993;18:13-5.
Moiseenko V, Liu M, Kristensen S, et al. Effect of bladder filling on doses to prostate and organs at risk: a treatment planning study. J Appl Clin Med Phys. 2006;8:55-68.
Sresty NV, Ramanjappa T, Raju AK, et al. Optimal usage of cone beam computed tomography system with different field of views in image guided radiotherapy (IGRT). Int J Cancer Ther Oncol. 2015; 3:334.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.